ArkBio's Ziresovir gains US FDA Phase II clinical trial approval

📅 17/08/2026 00:00 📰 m2pharma 👁️ 3 lectures 🌍 États-Unis 📂 Science

17 August 2026 - Shanghai Ark Biopharmaceutical Co Ltd (ArkBio) a China-based biopharmaceutical company, announced on Friday that the US Food and Drug Administration (FDA) has approved ziresovir (AK05...